Rocket Pharmaceuticals, Inc.
corporate_fare Company Profile
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for RCKT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for RCKT spans 10-Q, 8-K, SC TO-I/A, SC TO-I.
Recent high-impact activity:
- Rocket Posts $49.2M Q3 Loss, $279.4M Cash, Runway Into Q3 2028
- Rocket Secures $150M Hercules Credit Facility, Issues 1.76M Warrants at $2.99
- Rocket Secures $150M Credit Facility from Hercules Capital, Extending Cash Runway
- FDA Aligns on 12-Patient Pivotal Phase 2 Design for RP-A501 in Danon Disease
- FDA Aligns on Pivotal Phase 2 Design for RP-A501 in Danon Disease
Financial Snapshot
Short Interest & Short Volume
9.07 days to coverFINRA reported short interest of 16,242,429 shares in RCKT as of the October 30, 2026 settlement, a 0.2% decrease from the prior period — about 9.1 days to cover at its recent average daily volume. On November 20, 2026, 35.6% of RCKT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.